VNRX RSI Chart
Last 7 days
-6.0%
Last 30 days
32.2%
Last 90 days
-25%
Trailing 12 Months
-49.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 220.2K | 0 | 0 | 0 |
2023 | 1.3M | 944.7K | 821.9K | 214.5K |
2022 | 1.6M | 1.6M | 1.4M | 1.3M |
2021 | 880.1K | 1.1M | 1.3M | 1.5M |
2020 | 193.4K | 284.4K | 267.3K | 666.0K |
2019 | 0 | 0 | 31.9K | 169.8K |
2014 | 0 | 0 | 54.1K | 42.4K |
2012 | 197.3K | 191.0K | 197.5K | 55.0K |
2011 | 0 | 0 | 0 | 208.1K |
2010 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 01, 2024 | butera salvatore thomas | sold (taxes) | -13,488 | 0.87 | -15,504 | ceo, volition veterinary |
Jan 24, 2024 | henshall mickie | acquired | - | - | 8,500 | - |
Jan 24, 2024 | michel gaetan | acquired | - | - | 42,925 | chief operating officer |
Jan 24, 2024 | micallef jacob vincent | acquired | - | - | 23,375 | chief scientific officer |
Jan 24, 2024 | forterre gael | acquired | - | - | 25,925 | chief commercial officer |
Jan 24, 2024 | batchelor ann-louise | acquired | - | - | 22,525 | group chief marketing officer |
Jan 24, 2024 | colman alan | acquired | - | - | 8,500 | - |
Jan 24, 2024 | futcher edward | acquired | - | - | 8,500 | - |
Jan 24, 2024 | barnes phillip | acquired | - | - | 8,500 | - |
Jan 24, 2024 | reynolds cameron john | acquired | - | - | 50,150 | president and ceo |
Which funds bought or sold VNRX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -10,554 | - | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | 4,957 | 93,810 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -1.27 | 4,121 | 101,438 | -% |
May 15, 2024 | Lagoda Investment Management, L.P. | added | 36.06 | 1,167,040 | 3,840,440 | 2.36% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -81.84 | -8,063 | 1,912 | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | added | 93.01 | 8,744 | 17,170 | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | reduced | -1.09 | 5,590 | 131,854 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -91.09 | - | - | -% |
May 14, 2024 | NORTHERN TRUST CORP | reduced | -0.18 | 3,463 | 67,667 | -% |
May 14, 2024 | Credit Agricole S A | sold off | -100 | -2,868 | - | -% |
Unveiling VolitionRX Ltd's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to VolitionRX Ltd)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
DHR | 196.9B | 23.7B | 44.73 | 8.29 | ||||
A | 45.2B | 6.7B | 36.57 | 6.71 | ||||
IDXX | 44.9B | 3.7B | 51.83 | 12.06 | ||||
DGX | 16.0B | 9.3B | 18.95 | 1.73 | ||||
NTRA | 13.1B | 1.2B | -35.76 | 10.81 | ||||
MEDP | 12.2B | 2.0B | 38.94 | 6.2 | ||||
CRL | 11.4B | 4.1B | 26.02 | 2.78 | ||||
EXAS | 9.3B | 2.5B | -38.69 | 3.67 | ||||
MID-CAP | ||||||||
GH | 3.1B | 603.7M | -6.73 | 5.14 | ||||
NEOG | 2.9B | 929.2M | 1.9K | 3.16 | ||||
SMALL-CAP | ||||||||
CDNA | 808.3M | 275.1M | -4.41 | 2.94 | ||||
ACRS | 84.8M | 31.1M | -1.1 | 2.73 | ||||
AWH | 33.0M | 9.2M | -2.24 | 3.6 | ||||
APDN | 2.5M | 5.5M | -0.2 | 0.45 | ||||
BIOC | 183.8K | 25.9M | -0.01 | 0.01 |
VolitionRX Ltd News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2014Q4 | 2014Q3 |
Revenue | - | 172 | - | 49.00 | - | 166 | 607 | 171 | 393 | 114 | 712 | 419 | 392 | 464 | 537 | - | 91.00 | 38.00 | 138 | 17.00 | - | 15.00 |
Operating Expenses | -4.8% | 8,556 | 8,985 | 8,818 | 9,765 | 9,195 | 8,130 | 8,026 | 8,139 | 7,791 | 8,799 | 7,588 | 5,925 | 6,111 | 5,666 | 4,505 | 5,218 | 5,872 | 3,725 | 4,193 | - | - |
S&GA Expenses | -11.9% | 1,673 | 1,899 | 1,568 | 1,669 | 1,707 | 1,678 | 1,525 | 1,774 | 1,599 | 1,858 | 837 | 562 | 427 | 339 | 245 | 216 | 274 | 248 | 196 | - | - |
R&D Expenses | 1.9% | 4,630 | 4,544 | 4,651 | 5,451 | 4,906 | 4,296 | 4,002 | 3,279 | 3,590 | 2,951 | 3,612 | 2,936 | 3,873 | 3,966 | 3,180 | 3,493 | 3,895 | 2,767 | 2,643 | - | - |
Interest Expenses | 33.2% | 77.00 | 58.00 | 54.00 | 58.00 | 51.00 | 57.00 | 38.00 | 37.00 | 41.00 | 35.00 | 39.00 | 40.00 | 42.00 | 39.00 | 35.00 | 23.00 | 34.00 | 61.00 | 32.00 | - | - |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1* | - | - | - | - | - | - | - |
Net Income | 3.7% | -8,472 | -8,799 | -8,453 | -9,551 | -8,872 | -7,336 | -7,812 | -7,732 | -7,718 | -8,108 | -7,181 | -5,574 | -6,125 | -5,160 | -4,335 | -5,043 | -5,859 | -3,557 | -4,180 | - | - |
Net Income Margin | 3.7% | -160.21* | -166.36* | -41.63* | -35.54* | -23.73* | -23.78* | -22.56* | -18.76* | -17.46* | -17.73* | -18.38* | -19.37* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -236.4% | -8,371 | 6,139 | -8,691 | -7,648 | -8,945 | -6,382 | -7,144 | -6,806 | 3,486 | -4,537 | -5,020 | -5,620 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -30.5% | 19,435 | 27,950 | 18,041 | 27,561 | 18,044 | 18,295 | 23,341 | 24,347 | 31,683 | 27,490 | 30,004 | 35,244 | 40,510 | 26,151 | 26,088 | 26,247 | 16,875 | 21,291 | 23,777 | 22,881 | 20,631 |
Current Assets | -38.4% | 13,470 | 21,854 | 12,197 | 21,507 | 11,958 | 12,172 | 17,674 | 18,649 | 25,957 | 21,979 | 24,418 | 29,392 | 34,669 | 20,332 | 22,165 | 22,419 | 13,101 | 17,556 | 20,307 | 19,244 | 17,072 |
Cash Equivalents | -43.2% | 11,772 | 20,730 | 10,809 | 19,743 | 10,011 | 10,867 | 16,416 | 16,730 | 23,732 | 20,581 | 22,902 | 27,913 | 33,062 | 19,445 | 20,928 | 21,305 | 11,970 | 16,966 | 19,697 | 18,511 | 16,166 |
Net PPE | -6.2% | 5,181 | 5,523 | 5,305 | 5,455 | 5,402 | 5,393 | 4,881 | 4,808 | 4,721 | 4,911 | 5,081 | 5,267 | 5,249 | 5,171 | 3,343 | 3,265 | 3,097 | 2,981 | 2,890 | 3,038 | 3,025 |
Liabilities | -1.7% | 36,055 | 36,663 | 20,892 | 22,443 | 21,025 | 21,422 | 20,502 | 20,268 | 20,873 | 9,768 | 8,823 | 8,614 | 9,347 | 9,857 | 7,126 | 7,583 | 7,690 | 7,093 | 5,975 | 6,498 | 5,520 |
Current Liabilities | -1.1% | 31,492 | 31,837 | 17,654 | 18,803 | 17,238 | 17,386 | 16,978 | 17,351 | 17,513 | 6,516 | 5,852 | 5,398 | 6,000 | 6,237 | 4,318 | 4,708 | 4,634 | 3,860 | 3,243 | 3,497 | 2,666 |
Long Term Debt | -7.0% | 3,373 | 3,625 | 2,086 | 2,452 | 2,549 | 2,779 | 2,275 | 1,743 | 2,032 | 2,271 | 2,028 | 2,220 | 2,391 | 2,607 | 1,831 | 1,914 | 2,063 | 2,195 | 1,732 | 3,001 | 1,797 |
LT Debt, Current | -4.7% | 1,150 | 1,207 | 1,258 | 1,199 | 1,121 | 1,067 | 1,065 | 1,085 | 1,333 | 798 | 760 | 822 | 841 | 841 | 765 | 693 | 613 | 648 | - | 563 | - |
LT Debt, Non Current | -100.0% | - | 3,625 | 2,086 | 2,452 | 2,549 | 2,779 | 2,275 | 1,743 | 2,032 | 2,271 | 2,028 | 2,220 | 2,391 | 2,607 | 1,831 | 1,914 | 2,063 | 2,195 | 1,732 | 1,956 | 1,797 |
Shareholder's Equity | -90.8% | -16,620 | -8,712 | - | 5,118 | -2,981 | -3,126 | 2,840 | 4,079 | 10,811 | 17,722 | 21,181 | 26,630 | 31,163 | 16,294 | 18,961 | 18,663 | 9,185 | 14,199 | 17,802 | 16,383 | 15,111 |
Retained Earnings | -4.1% | -210,943 | -202,576 | -193,878 | -185,507 | -176,036 | -167,257 | -160,015 | -152,272 | -144,622 | -136,988 | -128,953 | -121,817 | -116,290 | -110,173 | -105,036 | -100,708 | -95,681 | -89,821 | -86,264 | -82,083 | -77,926 |
Additional Paid-In Capital | 0.3% | 194,997 | 194,448 | 191,518 | 191,065 | 173,467 | 164,397 | 162,940 | 156,442 | 155,655 | 154,731 | 150,221 | 148,468 | 147,382 | 126,526 | 124,122 | 118,916 | 104,326 | 103,854 | 103,374 | 98,178 | 92,800 |
Shares Outstanding | 0.3% | 82,109 | 81,898 | 78,342 | 78,136 | 63,112 | 57,873 | 57,496 | 53,847 | 53,790 | 53,772 | 53,224 | 53,144 | - | - | - | - | - | - | - | - | - |
Minority Interest | -11.5% | -1,014 | -909 | -808 | -725 | -645 | -551 | - | -388 | - | -222 | - | - | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 82,182 | - | - | - | 73,353 | - | - | - | 115,639 | - | - | - | 111,768 | - | - | - | 72,468 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -229.4% | -8,342 | 6,448 | -8,418 | -7,347 | -8,744 | -5,803 | -6,819 | -6,265 | 3,610 | -4,409 | -4,878 | -5,401 | -6,165 | -2,734 | -4,499 | -4,430 | -4,798 | -2,598 | -3,717 | -2,772 | -3,650 |
Share Based Compensation | -11.7% | 411 | 466 | 538 | 592 | 694 | 706 | 639 | 854 | 915 | - | 768 | - | - | 530 | 308 | 388 | 165 | 368 | 371 | 382 | 338 |
Cashflow From Investing | 74.5% | -78.81 | -308 | -273 | -301 | -200 | -578 | -325 | -541 | -124 | -128 | -141 | -219 | -483 | -1,065 | 15.00 | -266 | -330 | -151 | -122 | -124 | -112 |
Cashflow From Financing | -105.6% | -209 | 3,770 | -274 | 17,340 | 8,147 | 926 | 6,727 | -460 | -254 | 2,097 | 51.00 | 501 | 20,208 | 2,139 | 4,601 | 14,082 | -202 | 535 | 4,638 | 5,187 | 6,570 |
Buy Backs | - | - | - | - | - | 32.00 | - | - | - | - | - | - | - | - | - | - | - | -54.43 | - | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues | ||
Service | $ 39,776 | $ 5,356 |
Product | 131,759 | 144,452 |
Total Revenues | 171,535 | 149,808 |
Operating Expenses | ||
Research and development | 4,629,527 | 4,905,678 |
General and administrative | 2,253,743 | 2,581,703 |
Sales and marketing | 1,672,769 | 1,707,457 |
Total Operating Expenses | 8,556,039 | 9,194,838 |
Operating Loss | (8,384,504) | (9,045,030) |
Other Income (Expenses) | ||
Grant income | 0 | 165,795 |
Interest income | 8,654 | 57,648 |
Interest expense | (77,233) | (51,322) |
Loss on change in fair value of warrant liability | (18,922) | 0 |
Total Other Income (Expenses) | (87,501) | 172,121 |
Net Loss | (8,472,005) | (8,872,909) |
Net Loss attributable to Non-Controlling Interest | 104,617 | 93,361 |
Net Loss attributable to VolitionRx Stockholders | (8,367,388) | (8,779,548) |
Other Comprehensive Income (Loss) | ||
Foreign currency translation adjustments | 15,026 | (56,478) |
Net Comprehensive Loss | $ (8,456,979) | $ (8,929,387) |
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Stockholders | $ (0.10) | $ (0.15) |
Weighted Average Shares Outstanding - Basic and Diluted | 81,956,660 | 60,176,975 |
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets | ||
Cash and cash equivalents | $ 11,772,163 | $ 20,729,983 |
Accounts receivable | 133,500 | 242,617 |
Prepaid expenses | 1,094,287 | 521,370 |
Other current assets | 470,103 | 360,125 |
Total Current Assets | 13,470,053 | 21,854,095 |
Property and equipment, net | 5,180,551 | 5,523,013 |
Operating lease right-of-use assets | 569,163 | 549,504 |
Intangible assets, net | 215,133 | 23,886 |
Total Assets | 19,434,900 | 27,950,498 |
Current Liabilities | ||
Accounts payable | 3,527,673 | 3,211,287 |
Accrued liabilities | 3,305,316 | 3,928,761 |
Deferred revenue | 23,000,000 | 23,000,000 |
Management and directors' fees payable | 60,246 | 59,625 |
Current portion of long-term debt | 1,149,944 | 1,207,007 |
Current portion of finance lease liabilities | 47,875 | 48,570 |
Current portion of operating lease liabilities | 201,047 | 199,323 |
Current portion of grant repayable | 54,700 | 55,855 |
Warrant liability | 145,571 | 126,649 |
Total Current Liabilities | 31,492,372 | 31,837,077 |
Long-term debt, net of current portion | 3,372,568 | 3,624,860 |
Finance lease liabilities, net of current portion | 379,667 | 400,022 |
Operating lease liabilities, net of current portion | 396,376 | 378,054 |
Grant repayable, net of current portion | 413,968 | 422,707 |
Total Long-Term Liabilities | 4,562,579 | 4,825,643 |
Total Liabilities | 36,054,951 | 36,662,720 |
Stockholders' Deficit | ||
Common Stock Authorized: 100,000,000 shares of common stock, at $0.001 par value per share Issued and outstanding: 82,108,972 shares and 81,898,321 shares, respectively | 82,109 | 81,898 |
Additional paid-in capital | 194,997,353 | 194,448,414 |
Accumulated other comprehensive income | 258,966 | 243,940 |
Accumulated deficit | (210,943,895) | (202,576,507) |
Total VolitionRx Limited Stockholders' Deficit | (15,605,467) | (7,802,255) |
Non-controlling interest | (1,014,584) | (909,967) |
Total Stockholders' Deficit | (16,620,051) | (8,712,222) |
Total Liabilities and Stockholders' Deficit | $ 19,434,900 | $ 27,950,498 |